BrightPath Biotherapeutics Co., Ltd. announced that it has entered into a purchase agreement with new investor EVO FUND and private placement to issue 17th Stock Acquisition Rights 150,000 units at an issue price of ¥9 per unit for the gross proceeds of ¥1,350,000, 18th Stock Acquisition Rights 120,000 units at an issue price of ¥8 per unit for the gross proceeds of ¥960,000 and 19th Stock Acquisition Rights 90,000 units at an issue price of ¥4 per unit for the gross proceeds of ¥360,000; aggregate gross proceeds of ¥2,670,000 on June 19, 2024. The transaction has been approved by shareholders and is expected to close on July 5, 2024. The minimum exercise price is ¥32 in both cases, but even at that price, the number of potential shares is 36,000,000.

Amount of funds raised ¥2,232,670,000 yen. Exercise price and terms of exercise price revision 17th Stock Acquisition Rights Initial exercise price ¥62, 18th Stock Acquisition Rights Initial exercise price ¥62 and 19th Stock Acquisition Rights: Initial exercise price ¥64. Total amount to be paid for the stock acquisition rights ¥2,670,000, Value of assets to be contributed upon exercise of the stock acquisition rights ¥2,250,000,000, Estimated issuance costs ¥20,000,000 and Estimated net amount: ¥2,232,670,000.

Exercise period 17th Stock Acquisition Rights and 18th Stock Acquisition Rights is from The period will be from July 8, 2024 (inclusive) to July 7, 2026 (inclusive) and 19th Stock Acquisition Rights is from The period will be from July 8, 2024 (inclusive) to July 7, 2027 (inclusive).